DE69524772D1 - Ophthalmologisches abgabesystem - Google Patents

Ophthalmologisches abgabesystem

Info

Publication number
DE69524772D1
DE69524772D1 DE69524772T DE69524772T DE69524772D1 DE 69524772 D1 DE69524772 D1 DE 69524772D1 DE 69524772 T DE69524772 T DE 69524772T DE 69524772 T DE69524772 T DE 69524772T DE 69524772 D1 DE69524772 D1 DE 69524772D1
Authority
DE
Germany
Prior art keywords
ophthalmological
delivery system
delivery
formulations
alginate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69524772T
Other languages
English (en)
Inventor
Smadar Cohen
Esther Lobel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ben Gurion University of the Negev Research and Development Authority Ltd
Teva Pharmaceutical Industries Ltd
Original Assignee
Ben Gurion University of the Negev Research and Development Authority Ltd
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ben Gurion University of the Negev Research and Development Authority Ltd, Teva Pharmaceutical Industries Ltd filed Critical Ben Gurion University of the Negev Research and Development Authority Ltd
Application granted granted Critical
Publication of DE69524772D1 publication Critical patent/DE69524772D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
DE69524772T 1994-06-20 1995-06-19 Ophthalmologisches abgabesystem Expired - Lifetime DE69524772D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26229494A 1994-06-20 1994-06-20
PCT/US1995/007789 WO1995035073A1 (en) 1994-06-20 1995-06-19 Ophthalmic delivery system

Publications (1)

Publication Number Publication Date
DE69524772D1 true DE69524772D1 (de) 2002-01-31

Family

ID=22996942

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69524772T Expired - Lifetime DE69524772D1 (de) 1994-06-20 1995-06-19 Ophthalmologisches abgabesystem

Country Status (6)

Country Link
US (1) US5776445A (de)
EP (1) EP0777451B1 (de)
AT (1) ATE210943T1 (de)
DE (1) DE69524772D1 (de)
IL (1) IL114193A (de)
WO (1) WO1995035073A1 (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106819A (en) * 1996-12-31 2000-08-22 Sucher; David F. Methods of treating headache and functional extraocular and intraocular myotendinitis
FR2777189B1 (fr) 1998-04-09 2001-04-06 Chauvin Lab Sa Composition ophtalmique comprenant un beta-bloquant
FR2779953B1 (fr) * 1998-06-22 2000-08-11 Codif International Sa Procede d'elaboration d'un produit cosmetique destine a proteger la peau contre les agressions resultant de la pollution de l'air ambiant
US6730691B1 (en) * 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US8858961B2 (en) * 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CA2477044A1 (en) * 2002-02-22 2003-09-04 Pharmacia Corporation Ophthalmic formulation with gum system
EP2316459B1 (de) 2002-07-29 2013-11-06 Rigel Pharmaceuticals, Inc. 2,4-Pyrimidindiaminen zur Behandlung oder Vorbeugung von Autoimmunerkrankungen
EP2314327B2 (de) * 2003-05-05 2017-09-20 Ben-Gurion University Of The Negev Research And Development Authority Injizierbare vernetzte polymere zusammensetzung und deren verwendung
ATE506953T1 (de) 2003-08-07 2011-05-15 Rigel Pharmaceuticals Inc 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
CA2551064A1 (en) * 2004-01-09 2005-07-21 Yissum Research Development Company Of The Hebrew University Of Jerusale M Compounds, pharmaceutical compositions and therapeutic methods of preventing and treating diseases and disorders associated with amyloid fibril formation
EP1720518B1 (de) * 2004-02-26 2009-08-12 Bausch & Lomb Incorporated Viskoelastische alginat-zusammensetzung, herstellungsverfahren und verpackung
US20060270592A1 (en) * 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
CA2505836C (en) * 2004-05-06 2013-08-27 Alcon Inc. Topical brimonidine tartrate formulations that lack chlorine dioxide
US20070004672A1 (en) * 2005-07-01 2007-01-04 Dharmendra Jani Long lasting alginate dry eye, related methods of manufacture and methods of use
CA2628570A1 (en) 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
JP2009528295A (ja) 2006-02-24 2009-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋ経路の阻害のための組成物および方法
DK2078026T3 (da) 2006-11-21 2012-04-30 Rigel Pharmaceuticals Inc Prodrug-salte af 2, 4-pyrimidinediamine-forbindelser og anvendelser deraf
WO2008088612A1 (en) * 2006-12-20 2008-07-24 Bausch & Lomb Incorporated Method of stimulating the production of mucin in the eye of a patient
US20080153908A1 (en) * 2006-12-20 2008-06-26 Jani Dharmendra M Method of Treating Mucin Deficiency with an Active Pharmaceutical and Related Composition
US7659259B2 (en) * 2006-12-21 2010-02-09 Bausch & Lomb Incorporated Method of treating inflammation of the eye
WO2008082948A2 (en) * 2006-12-29 2008-07-10 Bausch & Lomb Incorporated Ophthalmic alginate composition related methods of manufacture and methods of use
CA2685230C (en) * 2007-05-04 2012-10-16 Bausch & Lomb Incorporated Compositions for reducing, ameliorating, treating, or preventing condition of dry eye and methods of making and using same
KR20100016285A (ko) * 2007-05-07 2010-02-12 보오슈 앤드 롬 인코포레이팃드 안구건조 상태를 감소, 개선, 치료 또는 예방하기 위한 조성물 및 이의 제조 및 사용 방법
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
WO2009105140A2 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
US20110046033A1 (en) 2008-01-31 2011-02-24 Jinzhong Zhang Multipurpose Lens Care Solution with Benefits to Corneal Epithelial Barrier Function
US9096819B2 (en) 2008-01-31 2015-08-04 Bausch & Lomb Incorporated Ophthalmic compositions with an amphoteric surfactant and an anionic biopolymer
US9481856B2 (en) * 2008-06-09 2016-11-01 Bausch & Lomb Incorporated Pharmaceutical formulations comprising stabilized polysaccharides and source of hydrogen peroxide
KR20110042282A (ko) * 2008-06-12 2011-04-26 노파르티스 아게 눈 전면에 대한 지속 전달제로서의 인 시츄 겔화 시스템
EP2346513A1 (de) * 2008-09-15 2011-07-27 Bausch & Lomb Incorporated Zusammensetzungen mit polymeren mit aminozuckereinheiten und verfahren zu ihrer herstellung und verwendung
US20100087550A1 (en) 2008-10-06 2010-04-08 Zora Marlowe Formulations with a Tertiary Amine Oxide
US8741930B2 (en) * 2008-10-24 2014-06-03 Bridge Pharma, Inc. Treating xerophthalmia with norketotifen
WO2010059894A1 (en) * 2008-11-21 2010-05-27 Bridge Pharma, Inc. Ocular formulations of norketotifen
JP5815411B2 (ja) 2008-12-30 2015-11-17 ライジェル ファーマシューティカルズ， インコーポレイテッド ピリミジンジアミンキナーゼ阻害剤
ES2473584T3 (es) 2009-01-23 2014-07-07 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
CN104523661A (zh) 2009-02-06 2015-04-22 南加利福尼亚大学 含有单萜的治疗组合物
JP5890182B2 (ja) 2009-02-12 2016-03-22 インセプト エルエルシー ヒドロゲルプラグによる薬物送達
US20110028503A1 (en) 2009-07-28 2011-02-03 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20110033545A1 (en) * 2009-08-06 2011-02-10 Absize, Inc. Topical pharmaceutical preparations having both a nanoparticle solution and a nanoparticle suspension and methods for the treatment of acute and chronic pain therewith
CN104744215B (zh) 2010-03-03 2019-03-15 尼昂克技术公司 包含单萜的药物组合物
KR101379370B1 (ko) 2010-04-24 2014-03-28 비아멧 파마슈티컬즈, 인코포레이티드 금속효소 억제제 화합물
MX347331B (es) 2010-07-28 2017-04-21 Rigel Pharmaceuticals Inc Composiciones y metodos para inhibicion de la via jak.
CN110464718A (zh) 2010-08-27 2019-11-19 尼昂克技术公司 包含poh衍生物的药物组合物
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
CA2816088A1 (en) 2010-10-28 2012-05-03 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
KR20180039185A (ko) 2010-11-13 2018-04-17 이노크린 파마슈티컬즈, 인크. 금속효소 억제제 화합물
CN103328452A (zh) 2010-12-13 2013-09-25 威尔金制药有限公司 金属酶抑制剂化合物
CN103517892B (zh) 2010-12-17 2016-01-27 尼昂克技术公司 使用异紫苏醇的方法和装置
EP2678297A2 (de) 2011-02-25 2014-01-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Chrysophaentin-analoga als hemmer des ftsz-proteins
US8883497B2 (en) 2011-04-28 2014-11-11 University Of Southern California Human myeloid derived suppressor cell cancer markers
WO2012177603A2 (en) 2011-06-19 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2012177635A1 (en) 2011-06-19 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CA2838916C (en) 2011-06-23 2020-08-11 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
US9309273B2 (en) 2011-12-11 2016-04-12 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
ES2774267T3 (es) 2012-01-20 2020-07-20 Mycovia Pharmaceuticals Inc Compuestos inhibidores de metaloenzimas
JP6231548B2 (ja) 2012-03-23 2017-11-15 マテオン セラピューティクス， インコーポレイテッド カテプシンの阻害のための組成物および方法
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
EP3007710B1 (de) 2013-06-13 2021-07-28 Orgenesis Ltd. Zellpopulationen, verfahren zur transdifferenzierung und verfahren zur verwendung davon
MA41296A (fr) 2014-12-30 2017-11-07 Orgenesis Ltd Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
AU2016219257B2 (en) 2015-02-12 2020-06-25 University Of Southern California Pharmaceutical compositions comprising perillyl alcohol derivatives
EP4279064A3 (de) 2015-05-12 2024-02-28 Incept, LLC Arzneimittelabgabe aus hydrogelen
JP6994454B2 (ja) 2015-08-04 2022-01-14 ライジェル ファーマシューティカルズ， インコーポレイテッド ベンズアゾール化合物ならびに該化合物の作製方法および使用方法
MX2018008105A (es) 2015-12-30 2018-11-12 Vps 3 Inc Compuestos inhibidores de metaloenzima.
WO2018005356A1 (en) 2016-06-27 2018-01-04 Rigel Pharmaceuticals, Inc. 2,4-diamino-pyrimidine compounds and method for making and using the compounds
CN110099899B (zh) 2016-10-26 2024-01-02 里格尔药品股份有限公司 用作irak抑制剂的噁唑衍生物及其制备方法
WO2018081294A1 (en) 2016-10-26 2018-05-03 Rigel Pharmaceuticals, Inc. Pyrazole amide compounds as irak inhibitors
US10858305B2 (en) 2016-11-30 2020-12-08 Neonc Technologies, Inc. Perillyl alcohol-3-bromopyruvate conjugate and methods of treating cancer
AU2017387033B2 (en) 2016-12-29 2024-02-01 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
EP3562306A4 (de) 2016-12-29 2020-06-24 Selenity Therapeutics (Bermuda), Ltd. Metalloenzym-inhibitor-verbindungen
EP3635106A4 (de) 2017-05-08 2021-01-06 Orgenesis Ltd. Transdifferenzierte zellpopulationen und verfahren zur verwendung davon
JP7167069B2 (ja) 2017-06-29 2022-11-08 ライジェル ファーマシューティカルズ， インコーポレイテッド キナーゼ阻害剤ならびに作製および使用のための方法
US20210292410A1 (en) 2017-12-07 2021-09-23 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
BR112020016074A2 (pt) 2018-02-08 2020-12-08 Neonc Technologies, Inc Métodos de permeabilização da barreira hematoencefálica
FI3788045T3 (fi) 2018-05-03 2023-06-28 Rigel Pharmaceuticals Inc RIP1-inhibitorisia yhdisteitä ja samojen valmistus- ja käyttömenetelmiä
DK3788044T3 (da) 2018-05-03 2023-10-02 Rigel Pharmaceuticals Inc RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse heraf
US20220000880A1 (en) 2018-11-01 2022-01-06 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
US20200377518A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
MX2022001596A (es) 2019-08-08 2022-03-11 Rigel Pharmaceuticals Inc Compuestos y metodos para tratar sindrome de liberacion de citocinas.
EP4013420B1 (de) 2019-08-14 2023-11-01 Rigel Pharmaceuticals, Inc. Verfahren zur blockierung oder linderung des zytokinfreisetzungssyndroms
JP2022545542A (ja) 2019-08-30 2022-10-27 ライジェル ファーマシューティカルズ， インコーポレイテッド ピラゾール化合物、その製剤並びに化合物及び／又は製剤を使用する方法
MX2022002717A (es) 2019-09-06 2022-08-10 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y metodos para prepararlos y usarlos.
KR20220042431A (ko) 2019-09-06 2022-04-05 리겔 파마슈티칼스, 인크. 헤테로시클릭 rip1 키나제 억제제
CN115298184A (zh) 2019-11-07 2022-11-04 里格尔药品股份有限公司 杂环rip1抑制化合物
US20220288047A1 (en) 2021-03-03 2022-09-15 Rigel Pharmaceuticals, Inc. Method for treating a disease or condition using a pyrazole compound or formulation thereof
TW202300490A (zh) 2021-03-11 2023-01-01 美商雷傑製藥公司 雜環rip1激酶抑制劑
TW202346291A (zh) 2022-03-23 2023-12-01 美商雷傑製藥公司 作為ｉｒａｋ抑制劑的嘧啶—２—基—吡唑化合物
US20230312568A1 (en) 2022-03-31 2023-10-05 Rigel Pharmaceuticals, Inc. Tricyclic irak inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4303676A (en) * 1980-03-21 1981-12-01 Balazs Endre A Hyaluronate based compositions and cosmetic formulations containing same
FR2588189B1 (fr) * 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DE3601132A1 (de) * 1986-01-16 1987-07-23 Christian Bannert Verfahren zur behandlung der schleimhaut
IT1203814B (it) * 1986-06-30 1989-02-23 Fidia Farmaceutici Esteri dell'acido alginico
US5200180A (en) * 1987-06-26 1993-04-06 Christian Bannert Pharmaceutical composition for the treatment of the human eye
IE63392B1 (en) * 1988-02-08 1995-04-19 Insite Vision Inc Ophthalmic suspensions
EP0357793B1 (de) * 1988-03-09 1994-05-25 Snow Brand Milk Products Co., Ltd. Zubereitung mit verzögerter freigabe durch verwendung von alginaten
FR2645439B1 (fr) * 1989-04-07 1991-06-21 Oreal Procede de preparation de capsules d'alginate(s) particulierement adaptees a un usage cosmetique, appareil pour sa mise en oeuvre et composition cosmetique contenant lesdites capsules
NO171069C (no) * 1990-05-29 1993-01-20 Protan Biopolymer As Kovalent tverrbundne, sterkt svellende alkalimetall- og ammonium-alginatgeler, samt fremgangsmaate for fremstilling derav
JP2536806B2 (ja) * 1991-03-27 1996-09-25 アルコン ラボラトリーズ インコーポレイテッド ゲル化多糖類と微粉砕された薬剤担体とを組み合わせた局部眼科用組成物

Also Published As

Publication number Publication date
IL114193A (en) 2000-02-29
WO1995035073A1 (en) 1995-12-28
IL114193A0 (en) 1995-10-31
US5776445A (en) 1998-07-07
EP0777451A4 (de) 1998-06-10
EP0777451A1 (de) 1997-06-11
ATE210943T1 (de) 2002-01-15
EP0777451B1 (de) 2001-12-19

Similar Documents

Publication Publication Date Title
DE69524772D1 (de) Ophthalmologisches abgabesystem
BR0014203A (pt) Formulações de suspensão tópicas contendo ciprofloxacina e dexametasona
AU6185398A (en) Charged lipids and uses for the same
FI970788A (fi) Kasveilla käytettäviksi tarkoitettuja suihkutettavissa olevia, kalvon muodostavia järjestelmiä vaikuttavien aineiden antamiseksi
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
DE69728678T2 (de) Hydrokolloid-wundgel
UA26455C2 (uk) Лікарський препарат у формі таблеток із сповільhеhим вивільhеhhям активhого іhгредієhта
FI953442A (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
DK0759687T3 (da) Anvendelse af gelpræparater som bejdsemidler
DE60016798D1 (de) Papiertuch enthaltend antivirale wirkstoffe die hautfreundlich sind
DE60002719D1 (de) Ophthalmische zusammensetzungen in form wässriger gele
ATE272389T1 (de) Verwendung einer lacrophyl zubereitung in augentropfen, die therapeutisch wirksame komponenten enthalten
DE69521122T2 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure-additions-salze
SE9403905D0 (sv) New formulations
DE3560313D1 (en) Improvements in or relating to anticonvulsant agents
SE9302203D0 (sv) Composition for ophthalmic use
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
MX9302272A (es) Retinoides solubles en agua.
KR950700685A (ko) 최음제로서 사용되는 요드화수소산(use of hydriodic acid as an aphrodisiac)
ES512751A0 (es) "procedimiento para la preparacion de un colirio antiseptico para afecciones oculares".
ES2132642T3 (es) Concentrados acuosos para suspension de endosulfan.
RU94036667A (ru) Биоэнергомодулятор
ECSP961924A (es) Formulacion pesticida

Legal Events

Date Code Title Description
8332 No legal effect for de